Research Publications

Technology overviews

Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications. N. Van Braeckel-Budimir, B.J. Haijema, K. Leenhouts Front. Immunol. 4 (2013):282. doi: 10.3389/fimmu.2013.00282

Mimopath-based vaccine delivery. K. Leenhouts. In: Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines (ed. M. Singh), (2013):245-265. Springer, New York.

read more >

Vaccine research articles

Recombinant soluble Respiratory Syncytial Virus F protein that lacks heptad repeat B, contains a GCN4 trimerization motif and is not cleaved displays prefusion-like characteristics. I. Widjaja, A. Rigter, S. Jacobino, F.J.M. van Kuppeveld, K. Leenhouts, C. Palomo, J.A. Melero, J.H.W. Leusen, B.J. Haijema, P.J.M. Rottier, C.A.M. de Haan. PLoS ONE 10(6) (2015): e0130829. doi:10.1371/journal.pone.0130829.

Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice. S.J. Heine, O.L. Franco-Mahecha, X. Chen, S. Choudhari, W.C. Blackwelder, M.L. van Roosmalen, K. Leenhouts, W.L. Picking, M.F. Pasetti. Immunol. Cell Biol. (2015):1-12.

Inactivated influenza vaccine adjuvanted with Bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion. C. Keijzer, B.J. Haijema, T. Meijerhof, P. Voorn, A. de Haan, K. Leenhouts, M.L. van Roosmalen, W. van Eden, F. Broere. Vaccine 32 (2014):2904-2910.

A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to Bacterium-like particles. A. Rigter, I. Widjaja, H. Versantvoort, F.E.J. Coenjaerts, M. van Roosmalen, K. Leenhouts, P.J.M. Rottier, B.J. Haijema, C.A.M. de Haan. PLoS ONE 8(8) (2013):e71072. doi:10.1371/journal.pone.0071072.

Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration. A. de Haan, B.J. Haijema, P. Voorn, T. Meijerhof, M.L. van Roosmalen, K. Leenhouts. Vaccine 30 (2012):4884-4891.

read more >

Other

Biophysical characterization of the Type III secretion system sranslocator proteins and the translocator proteins attached to Bacterium-Like Particles. X. Chen, S.P. Choudhari, P. Kumar, R.T. Toth IV, J.H. Kim, M.L. van Roosmalen, K. Leenhouts, C.R. Middaugh, W.L. Picking, W.D. Picking. J. Pharm. Sci. 104 (2015): DOI 10.1002/jps.24659.

read more >

07.11.16 Mucosis Initiates First-in-Human Study of SynGEM®, a Needle-Free Nasal Spray RSV Vaccine
more >

24.03.16 Mucosis to Present at World Vaccines Congress 2016
more >

20.01.16 Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London
more >

19.05.15 Mucosis to Present Data on Intranasal RSV Vaccine SynGEM® at Modern Vaccines Adjuvants & Delivery Systems 2015
more >

23.03.15 Mucosis to Present on Intranasal Respiratory Syncytial Virus Vaccine Candidate SynGEM® at BioCapital Europe
more >

10.11.14 Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium
more >

20.10.14 Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference
more >